Effects of rivastigmine on cognitive function in patients with traumatic brain injury

J. M. Silver, B. Koumaras, M. Chen, D. Mirski, S. G. Potkin, P. Reyes, D. Warden, Philip D Harvey, D. Arciniegas, D. I. Katz, I. Gunay

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

OBJECTIVE: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. METHODS: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A′ subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A′ or HVLT. RESULTS: The percentage of responders at week 12 on either the CANTAB RVIP A′ or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. CONCLUSIONS: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.

Original languageEnglish
Pages (from-to)748-755
Number of pages8
JournalNeurology
Volume67
Issue number5
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Rivastigmine
Verbal Learning
Cognition
Neuropsychological Tests
Automatic Data Processing
Placebos
Memory Disorders
Traumatic Brain Injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Silver, J. M., Koumaras, B., Chen, M., Mirski, D., Potkin, S. G., Reyes, P., ... Gunay, I. (2006). Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology, 67(5), 748-755. https://doi.org/10.1212/01.wnl.0000234062.98062.e9

Effects of rivastigmine on cognitive function in patients with traumatic brain injury. / Silver, J. M.; Koumaras, B.; Chen, M.; Mirski, D.; Potkin, S. G.; Reyes, P.; Warden, D.; Harvey, Philip D; Arciniegas, D.; Katz, D. I.; Gunay, I.

In: Neurology, Vol. 67, No. 5, 01.09.2006, p. 748-755.

Research output: Contribution to journalArticle

Silver, JM, Koumaras, B, Chen, M, Mirski, D, Potkin, SG, Reyes, P, Warden, D, Harvey, PD, Arciniegas, D, Katz, DI & Gunay, I 2006, 'Effects of rivastigmine on cognitive function in patients with traumatic brain injury', Neurology, vol. 67, no. 5, pp. 748-755. https://doi.org/10.1212/01.wnl.0000234062.98062.e9
Silver JM, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology. 2006 Sep 1;67(5):748-755. https://doi.org/10.1212/01.wnl.0000234062.98062.e9
Silver, J. M. ; Koumaras, B. ; Chen, M. ; Mirski, D. ; Potkin, S. G. ; Reyes, P. ; Warden, D. ; Harvey, Philip D ; Arciniegas, D. ; Katz, D. I. ; Gunay, I. / Effects of rivastigmine on cognitive function in patients with traumatic brain injury. In: Neurology. 2006 ; Vol. 67, No. 5. pp. 748-755.
@article{843277487bf449b4a1383331a3786426,
title = "Effects of rivastigmine on cognitive function in patients with traumatic brain injury",
abstract = "OBJECTIVE: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. METHODS: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A′ subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A′ or HVLT. RESULTS: The percentage of responders at week 12 on either the CANTAB RVIP A′ or HVLT was 48.7{\%} for rivastigmine and 49.3{\%} for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25{\%} impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. CONCLUSIONS: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.",
author = "Silver, {J. M.} and B. Koumaras and M. Chen and D. Mirski and Potkin, {S. G.} and P. Reyes and D. Warden and Harvey, {Philip D} and D. Arciniegas and Katz, {D. I.} and I. Gunay",
year = "2006",
month = "9",
day = "1",
doi = "10.1212/01.wnl.0000234062.98062.e9",
language = "English",
volume = "67",
pages = "748--755",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effects of rivastigmine on cognitive function in patients with traumatic brain injury

AU - Silver, J. M.

AU - Koumaras, B.

AU - Chen, M.

AU - Mirski, D.

AU - Potkin, S. G.

AU - Reyes, P.

AU - Warden, D.

AU - Harvey, Philip D

AU - Arciniegas, D.

AU - Katz, D. I.

AU - Gunay, I.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - OBJECTIVE: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. METHODS: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A′ subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A′ or HVLT. RESULTS: The percentage of responders at week 12 on either the CANTAB RVIP A′ or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. CONCLUSIONS: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.

AB - OBJECTIVE: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. METHODS: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A′ subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A′ or HVLT. RESULTS: The percentage of responders at week 12 on either the CANTAB RVIP A′ or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. CONCLUSIONS: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.

UR - http://www.scopus.com/inward/record.url?scp=33748698276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748698276&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000234062.98062.e9

DO - 10.1212/01.wnl.0000234062.98062.e9

M3 - Article

C2 - 16966534

AN - SCOPUS:33748698276

VL - 67

SP - 748

EP - 755

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -